M Sivanandham - JoVE Visualize

Showing results (11-20 of 19) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 19 results.

Annals of Surgical Oncology|March 1, 1996

Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trialM K Wallack, M Sivanandham, B Whooley, et al.

Head & Neck|October 10, 1997

Adjuvant immunotherapy for patients with melanoma: are patients with melanoma of the head and neck candidates for this therapy?P M Shaw, M Sivanandham, S F Bernik, et al.

Surgical Oncology|November 24, 2001

Overview analysis of adjuvant therapies for melanoma--a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trialsE M Kim, M Sivanandham, C I Stavropoulos, et al.

Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1990

Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic responseN G Chakraborty, D R Twardzik, M Sivanandham, et al.

The Journal of Experimental Medicine|June 1, 1989

Clonal analysis of cytotoxic and regulatory T cell responses against human melanomaB Mukherji, A Guha, N G Chakraborty, et al.

Hybridoma|February 1, 1997

Combinatorial antibodies against human malignant melanomaS Pereira, P Van Belle, D Elder, et al.

Cancer|January 1, 1995

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanomaM K Wallack, M Sivanandham, C M Balch, et al.

Journal of the American College of Surgeons|July 11, 1998

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trialM K Wallack, M Sivanandham, C M Balch, et al.

Annals of Surgery|August 1, 1997

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trialM K Wallack, M Sivanandham, K Ditaranto, et al.

Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 19 results.

Annals of Surgical Oncology|March 1, 1996

Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trialM K Wallack, M Sivanandham, B Whooley, et al.

Head & Neck|October 10, 1997

Adjuvant immunotherapy for patients with melanoma: are patients with melanoma of the head and neck candidates for this therapy?P M Shaw, M Sivanandham, S F Bernik, et al.

Surgical Oncology|November 24, 2001

Overview analysis of adjuvant therapies for melanoma--a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trialsE M Kim, M Sivanandham, C I Stavropoulos, et al.

Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1990

Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic responseN G Chakraborty, D R Twardzik, M Sivanandham, et al.

The Journal of Experimental Medicine|June 1, 1989

Clonal analysis of cytotoxic and regulatory T cell responses against human melanomaB Mukherji, A Guha, N G Chakraborty, et al.

Hybridoma|February 1, 1997

Combinatorial antibodies against human malignant melanomaS Pereira, P Van Belle, D Elder, et al.

Cancer|January 1, 1995

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanomaM K Wallack, M Sivanandham, C M Balch, et al.

Journal of the American College of Surgeons|July 11, 1998

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trialM K Wallack, M Sivanandham, C M Balch, et al.

Annals of Surgery|August 1, 1997

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trialM K Wallack, M Sivanandham, K Ditaranto, et al.

Pageof 2